한글목차

세계의 바이오의약품 산업에 대해 조사 분석했으며, 2019년부터 2025년까지 1,390건의 재생의료 공동 연구 및 라이선싱 계약에 관한 계약 조건 등의 상세한 데이터를 정리하여 전해드립니다.

목차

주요 요약

제1장 소개

제2장 재생의료 계약 동향

• 소개
• 지난 몇 년간 재생의료 계약
• 가장 활발한 재생의료 교섭자
• 재생의료 계약 : 계약 유형별
• 재생의료 계약 : 치료 분야별
• 재생의료 계약 : 산업 부문별
• 재생의료 계약의 계약 조건
  • 재생의료 계약 헤드라인 금액
  • 재생의료 계약 선급금
  • 재생의료 계약 단계별 기술료
  • 재생의료 로열티율

제3장 주요 재생의료 계약

• 소개
• 상위 재생의료 계약(금액)

제4장 가장 활발한 재생의료 교섭자

• 소개
• 가장 활발한 재생의료 교섭자
• 가장 활발한 재생의료 계약 기업 개요

제5장 재생의료 계약 디렉토리

• 소개
• 재생의료 계약 디렉토리

제6장 재생의료 계약 : 기술 유형별

• 계약 디렉토리
• 계약 디렉토리 - 재생의료 계약 : 기업별(A-Z)
• 계약 디렉토리 - 재생의료 계약 : 계약 유형별
• 계약 디렉토리 - 재생의료 계약 : 치료 분야별
• 계약 유형의 정의
• Biopharma Research Ltd에 대해
• Current Partnering
• Current Agreements
• Current Partnering의 최근 보고서 제목

영문목차

Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of regenerative medicine deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1390 regenerative medicine deals announced since 2016 including financial terms where available including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of regenerative medicine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2019.

Chapter 3 provides an overview of the leading regenerative medicine deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in regenerative medicine dealmaking with a brief summary followed by a comprehensive listing of regenerative medicine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of regenerative medicine deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since Jan 2019. The chapter is organized by specific regenerative medicine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in regenerative medicine deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Regenerative Medicine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse regenerative medicine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Regenerative Medicine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of regenerative medicine trends and structure of deals entered into by leading biopharma companies worldwide.

Regenerative Medicine Collaboration and Licensing Deals includes:

• Trends in regenerative medicine dealmaking in the biopharma industry
• Directory of regenerative medicine deal records covering pharmaceutical and biotechnology
• The leading regenerative medicine deals by value
• Most active regenerative medicine licensing dealmakers
• Regenerative Medicine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in regenerative medicine dealmaking

• 2.1. Introduction
• 2.2. Regenerative medicine deals over the years
• 2.3. Most active regenerative medicine dealmakers
• 2.4. Regenerative medicine deals by deal type
• 2.5. Regenerative medicine deals by therapy area
• 2.6. Regenerative medicine deals by industry sector
• 2.7. Deal terms for regenerative medicine deals
  • 2.7.1 Regenerative medicine deals headline values
  • 2.7.2 Regenerative medicine deal upfront payments
  • 2.7.3 Regenerative medicine deal milestone payments
  • 2.7.4 Regenerative medicine royalty rates

Chapter 3 - Leading regenerative medicine deals

• 3.1. Introduction
• 3.2. Top regenerative medicine deals by value

Chapter 4 - Most active regenerative medicine dealmakers

• 4.1. Introduction
• 4.2. Most active regenerative medicine dealmakers
• 4.3. Most active regenerative medicine deals company profiles

Chapter 5 - Regenerative medicine contracts dealmaking directory

• 5.1. Introduction
• 5.2. Regenerative medicine contracts dealmaking directory

Chapter 6 - Regenerative medicine dealmaking by technology type

• Deal directory
• Deal directory - Regenerative medicine deals by company A-Z
• Deal directory - Regenerative medicine deals by deal type
• Deal directory - Regenerative medicine deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Regenerative medicine deals since 2019
• Figure 2: Active regenerative medicine dealmaking activity - 2019 - 2025
• Figure 3: Regenerative medicine deals by deal type since 2019
• Figure 4: Regenerative medicine deals by therapy area since 2019
• Figure 5: Regenerative medicine deals by industry sector since 2019
• Figure 6: Regenerative medicine deals with a headline value
• Figure 7: Regenerative medicine deals with an upfront value
• Figure 8: Regenerative medicine deals with a milestone value
• Figure 9: Regenerative medicine deals with a royalty rate value
• Figure 10: Top regenerative medicine deals by value since 2019
• Figure 11: Most active regenerative medicine dealmakers 2019 - 2025
• Figure 12: Regenerative medicine deals by technology type since 2019